Operational efficiency remains severely impaired, as demonstrated by a negative free cash flow margin of -19.3% in 2026Q1 and a history of questionable capital allocation, including a $588K dividend payment during a period of significant operating losses.
Mangoceuticals, Inc. (MGRX) cash flow statement — 5-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Cash from Operations | -3.89M | -5.85M | -4.86M | -7M | -1.35M | -17.52K |
| Operating CF Margin % | - | -1282.89% | -789.74% | -956.59% | -15063.41% | - |
| Operating CF Growth % | 119.74% | -20.28% | 30.49% | -419.66% | -7585.6% | - |
| Net Income | -15.1M | -20.64M | -8.71M | -9.21M | -2M | -17.7K |
| Depreciation & Amortization | 1.02M | 1.72M | 731.47K | 24.89K | 3.86K | 0 |
| Stock-Based Compensation | 2.17M | 1.17M | 248.68K | 624.46K | 234.09K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | -151.82K | 0 |
| Other Non-Cash Items | 7.77M | 10.93M | 2.2M | 1.52M | 546.54K | 181 |
| Working Capital Changes | 262.61K | 970.47K | 660.38K | 41.51K | 18.87K | 0 |
| Change in Receivables | 0 | -20.06K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 98.23K | 55.67K | 696.74K | 107.09K | 33.67K | 0 |
| Cash from Investing | 0 | 0 | 65K | -3.52K | -43.1K | 0 |
| Capital Expenditures | 0 | 0 | 0 | -3.52K | -43.1K | 0 |
| CapEx % of Revenue | 0% | 0% | - | 0.48% | 482.18% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 65K | 0 | 0 | 0 |
| Cash from Financing | 4.02M | 7.27M | 4.13M | 7.06M | 2.05M | 40.07K |
| Debt Issued (Net) | -86.56K | 468.5K | 150K | -167.46K | 49.93K | 39.27K |
| Equity Issued (Net) | 2.96M | 5.65M | 3.98M | 6.2M | 2M | 800 |
| Dividends Paid | -588K | 0 | -802.11K | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.74M | 1.15M | 802.11K | 1.02M | 0 | 0 |
| Net Change in Cash | 127.67K | 1.43M | -680.35K | 56.15K | 660.31K | 22.55K |
| Free Cash Flow | -3.89M | -5.85M | -4.86M | -7M | -1.39M | -17.52K |
| FCF Margin % | -1234.31% | -1282.89% | -789.74% | -957.07% | -15545.59% | - |
| FCF Growth % | 33.22% | -20.28% | 30.53% | -403.8% | -7831.62% | - |
| FCF per Share | -0.23 | -0.58 | -2.46 | -4.90 | -1.20 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.26x | 0.28x | 0.56x | 0.76x | 0.67x | 0.99x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MGRX stock.
Mangoceuticals, Inc. (MGRX) generated $-5.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Mangoceuticals, Inc. (MGRX) reported negative free cash flow of $5.9M in 2025, indicating capital requirements exceeded cash from operations.
Mangoceuticals, Inc. (MGRX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Unsustainable cash burn rate
Metrics are mathematically derived from official filings.
Persistent Disconnect Between Earnings Reality
According to historical financial data, MGRX consistently reports net losses that far exceed operating cash outflows, with OCF/NI ratios frequently below 0.50, suggesting that non-cash charges like stock-based compensation are masking the true severity of the company's underlying cash-generative deficiencies and operational inefficiencies.
The persistent gap between net income and operating cash flow indicates that the company's accounting losses are not merely non-cash accounting artifacts but reflect a fundamental inability to generate positive cash from core operations. Investors should monitor whether the reliance on stock-based compensation to bridge this gap will continue to dilute equity holders while failing to improve the underlying cash conversion cycle.
Negative Free Cash Flow Trajectory
As reported in quarterly filings, MGRX has maintained a consistently negative free cash flow trajectory, with FCF margins reaching as low as -20.8% in 2025Q1, indicating that the business model is currently incapable of self-funding its operations without continuous external capital injections.
The absence of positive free cash flow, even in periods of lower reported losses, suggests that the company's cost structure is fundamentally misaligned with its revenue-generating capacity. This trajectory implies that the firm remains in a perpetual state of cash consumption, which warrants extreme caution regarding its long-term solvency.
Working Capital Volatility Signals Instability
Based on the provided cash flow statements, working capital changes have been highly erratic, swinging from a $915.8K inflow in 2024Q1 to a $432.3K outflow in 2025Q3, which suggests significant instability in the company's ability to manage its payables and receivables effectively.
Such volatility in working capital often points to inconsistent collection cycles or aggressive attempts to manage cash by delaying payments to vendors. This behavior may indicate that the company is struggling to maintain stable relationships with its pharmacy partners, potentially threatening the continuity of its supply chain.
Capital Allocation Amidst Cash Scarcity
As evidenced by the 2025Q2 dividend payment of $588K, MGRX has historically prioritized capital returns despite generating significant operating losses, a decision that appears highly questionable given the company's limited cash reserves and the urgent need for liquidity to fund its core business operations.
The decision to pay dividends while the company is burning cash at an unsustainable rate suggests a potential misalignment between capital allocation strategy and the firm's actual financial health. This practice likely accelerated the depletion of the company's cash balance, leaving it in a more precarious position to navigate its current operational challenges.